The Telix Pharmaceuticals Ltd (ASX: TLX) share price is in focus today after the company announced the US FDA has granted Fast Track designation for its BiPASS program, which targets earlier and less invasive prostate cancer diagnosis.
Image source: Getty Images
What did Telix Pharmaceuticals report?
- Received FDA Fast Track designation for BiPASS, a pre-biopsy prostate cancer imaging program.
- BiPASS evaluates gallium-68 PSMA-PET imaging alongside MRI to guide prostate cancer diagnosis before biopsy.
- Completed Phase 3 patient enrollment for BiPASS, using Illuccix and Gozellix agents.
- Engaged positively with FDA, planning for a new drug application (NDA) to expand access to this imaging method.
- Clinical data shows combining PSMA-PET and MRI can reduce unnecessary biopsies by nearly 50%.
What else do investors need to know?
Telix Pharmaceuticals' BiPASS program aims to address a significant unmet need. Currently, over three million prostate biopsies are performed worldwide each year, but up to 75% yield negative results, making many procedures unnecessary and stressful for patients.
The FDA's Fast Track designation means Telix can engage with the regulator more frequently and could have its submission for approval reviewed more quickly. If approved, the BiPASS approach may broaden the use of advanced imaging in prostate cancer care.
In addition, the company's commercial products, Illuccix and Gozellix, are already approved in multiple global markets for imaging PSMA-positive prostate cancer. However, their use in pre-biopsy diagnosis remains investigational.
What did Telix Pharmaceuticals management say?
Dr. David N. Cade, Group Chief Medical Officer at Telix, said:
Fast Track designation reflects the FDA's recognition of the potential for BiPASS to address an important unmet need in the prostate cancer diagnostic pathway. We believe gallium-68 PSMA-PET, used alongside MRI, could help physicians make more informed decisions before biopsy, improve diagnostic confidence and potentially reduce unnecessary invasive procedures for patients. This designation supports continued close engagement with the FDA as we advance BiPASS toward an NDA submission.
What's next for Telix Pharmaceuticals?
Telix plans to submit a new drug application (NDA) for BiPASS to the FDA, seeking approval for use before invasive prostate biopsies. If successful, this could open up a larger market and provide faster, less stressful diagnostic options for many patients.
The business continues to build on a broad pipeline, with late-stage programmes for prostate, brain, and kidney cancers, and aims to establish further growth in international markets.
Telix Pharmaceuticals share price snapshot
Over the past 12 months, the Telix Pharmaceuticals share price has risen 11%, outperforming the S&P/ASX 200 Index (ASX: XJO), which has declined 2% over the same period.
